Skip to content

Insider · CIK 0001595153

O. Temple Sloan III

director

Files at FBNC (FIRST BANCORP /NC/). First filing -, latest -.

O. Temple Sloan III files SEC Form 4 as director at FBNC (FIRST BANCORP /NC/). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; O. Temple Sloan III has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jun 1, 2026FBNC
FIRST BANCORP /NC/
AGrant or award
Common Stock
+863$57.99$50k17,383Jun 3, 2026
Jun 4, 2025FBNC
FIRST BANCORP /NC/
AGrant or award
Common Stock
+923$40.63$38k16,520Jun 6, 2025

Questions about O. Temple Sloan III

Answered from the filings on this page, as of the latest one.

Is O. Temple Sloan III buying or selling?

O. Temple Sloan III has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did O. Temple Sloan III's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and O. Temple Sloan III has 0.

Where does O. Temple Sloan III file Form 4?

O. Temple Sloan III has filed Form 4 at FBNC (FIRST BANCORP /NC/). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.